EDCTP SimpliciTB 2018

Gillespie, Stephen Henry (PI)

School of Medicine

Project: Standard

2 Article

2 results

2024
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Cevik, M., Thompson, L. C., Upton, C., Rolla, V. C., Malahleha, M., Mmbaga, B., Ngubane, N., Abu Bakar, Z., Rassool, M., Variava, E., Dawson, R., Staples, S., Lalloo, U., Louw, C., Conradie, F., Eristavi, M., Samoilova, A., Skornyakov, S. N., Ntinginya, N. E. & Haraka, F. & 28 others, Praygod, G., Mayanja-Kizza, H., Caoili, J., Balanag, V., Dalcolmo, M. P., McHugh, T., Hunt, R., Solanki, P., Bateson, A., Crook, A. M., Fabiane, S., Timm, J., Sun, E., Spigelman, M., Sloan, D. J., Gillespie, S. H., Bruinenberg, P., Beumont, M., Nedelman, J., Li, M., Zuma-Gwala, N., Rajaram, S., Choo, L., Wills, G., Betteridge, M., Leandra, L., Olugbosi, M. & Borisov, S., 1 Sept 2024, In: The Lancet Infectious Diseases. 24, 9, p. 1003-1014 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Tweed, C. D., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V., Ban, A. Y. L., Bateson, A. L. C., Betteridge, M. C., Brumskine, W., Caoili, J., Chaisson, R. E., Cevik, M., Conradie, F., Dawson, R., del Parigi, A., Diacon, A., Everitt, D. E., Fabiane, S. M., Hunt, R. & Ismail, A. I. & 19 others, Lalloo, U., Lombard, L., Louw, C., Malahleha, M., McHugh, T. D., Mendel, C. M., Mhimbira, F., Moodliar, R. N., Nduba, V., Nunn, A. J., Sabi, I., Sebe, M. A., Selepe, R. A. P., Staples, S., Swindells, S., van Niekerk, C. H., Variava, E., Spigelman, M. & Gillespie, S. H., 1 Apr 2021, In: International Journal of Tuberculosis and Lung Disease. 25, 4, p. 305-314 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

EDCTP SimpliciTB 2018

Research output

Search results

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB